Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Accured Expenses (2016 - 2025)

Fate Therapeutics' Change in Accured Expenses history spans 14 years, with the latest figure at $865000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 32.06% year-over-year to $865000.0; the TTM value through Dec 2025 reached -$9.0 million, down 443.47%, while the annual FY2025 figure was -$9.0 million, 443.47% down from the prior year.
  • Change in Accured Expenses reached $865000.0 in Q4 2025 per FATE's latest filing, up from -$550000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $10.3 million in Q3 2022 to a low of -$20.4 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$973450.0, with a median of $402000.0 recorded in 2024.
  • The largest YoY upside for Change in Accured Expenses was 309.41% in 2021 against a maximum downside of 1068.28% in 2021.
  • A 5-year view of Change in Accured Expenses shows it stood at -$10.4 million in 2021, then surged by 132.63% to $3.4 million in 2022, then plummeted by 155.89% to -$1.9 million in 2023, then skyrocketed by 134.6% to $655000.0 in 2024, then soared by 32.06% to $865000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Change in Accured Expenses are $865000.0 (Q4 2025), -$550000.0 (Q3 2025), and $484000.0 (Q2 2025).